Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 118-125

  Krane, L Spencer ^a   Kaul, Sanjeev A ^a   Stricker, Hans J ^a   Peabody, James O ^a   Menon, Mani ^a   Agarwal, Piyush K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

hydroxymethylglutaryl CoA reductase inhibitors; prostatectomy; prostatic neoplasms

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 71449100496     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.151     Document Type: Article

References (26)

1. Mann D., Reynolds K., Smith D., et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42 (2008) 1208
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267
3. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117
4. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495
5. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498
6. Cyrus-David M.S., Weinberg A., Thompson T., et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173 (2005) 1923
7. Hamilton R.J., Goldberg K.C., Platz E.A., et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100 (2008) 1511
8. Hamilton R.J., and Freedland S.J. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 18 (2008) 333
9. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66 (2005) 1150
10. Werny D.M., Saraiya M., and Gregg E.W. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 164 (2006) 978
11. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540
12. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162 (2005) 318
13. Browning D.R., and Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120 (2007) 833
14. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74
15. Friedman G.D., Flick E.D., Udaltsova N., et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17 (2008) 27
16. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819
17. Jacobs E.J., Rodriguez C., Bain E.B., et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16 (2007) 2213
18. Murtola T.J., Tammela T.L., Lahtela J., et al. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16 (2007) 2226
19. Flick E.D., Habel L.A., Chan K.A., et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16 (2007) 2218
20. Boudreau D.M., Yu O., Buist D.S., et al. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19 (2008) 767
21. Freeman M.R., and Solomon K.R. Cholesterol and prostate cancer. J Cell Biochem 91 (2004) 54
22. Hall S.A., Page S.T., Travison T.G., et al. Do statins affect androgen levels in men?. Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 16 (2007) 1587
23. Soto D.E., Daignault S., Sandler H.M., et al. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73 (2009) 158
24. Mills I.W., Crossland A., Patel A., et al. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 52 (2007) 503
25. Banez L.L., Hamilton R.J., Partin A.W., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (2007) 2275
26. Colli J.L., and Amling C.L. High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol 27 (2009) 170